title: [EFFICIENCY OF COMBINATION OF ROFLUMILAST AND QUERCETIN FOR CORRECTION OXYGEN- INDEPENDENT MECHANISMS AND PHAGOCYTIC ACTIVITY OF MACROPHAGE CELLS OF PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHEN COMBINED WITH CORONARY HEART DISEASE].
abstract: Studied oxygen independent reaction and phagocytic activity of macrophage cells of patients with chronic obstructive pulmonary disease (COPD) II-III stage when combined with coronary heart disease (CHD). The increasing oxygen independent reactions monocytes and neutrophils and a decrease of the parameters that characterize the functional state of phagocytic cells, indicating a decrease in the functional capacity of macrophage phagocytic system (MPS) in patients with acute exacerbation of COPD, which runs as its own or in combination with stable coronary heart disease angina I-II. FC. Severity immunodeficiency state in terms of cellular component of nonspecific immunity in patients with acute exacerbation of COPD II-III stage in conjunction with the accompanying CHD increases with the progression of heart failure. Inclusion of basic therapy of COPD exacerbation and standard treatment of coronary artery disease and drug combinations Roflumilastand quercetin causes normalization of phagocytic indices MFS, indicating improved immune status and improves myocardial perfusion in terms of daily ECG monitoring.
authors.forename: P
authors.initials: P
authors.lastname: Gerych
authors.forename: R
authors.initials: R
authors.lastname: Yatsyshyn
mesh_terms: D000631:Aminopyridines / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001549:Benzamides / Q000627:therapeutic use*; D002316:Cardiotonic Agents; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D003521:Cyclopropanes / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008297:Male; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D010587:Phagocytosis / Q000187:drug effects*; D061251:Primary Cell Culture; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011794:Quercetin / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D001549:Benzamides; D002316:Cardiotonic Agents; D003521:Cyclopropanes; C424423:Roflumilast; D011794:Quercetin